uniQure N.V. 8-K

What Happened
uniQure N.V. announced on June 23, 2026 (reported in an 8-K filed June 24, 2026) that it entered into an underwriting agreement with Leerink Partners LLC to sell 4,945,055 ordinary shares in an underwritten public offering at $45.50 per share. The underwriters had a 30‑day option to buy an additional 741,758 shares, which they exercised in full on June 24, 2026, bringing the total shares offered to 5,686,813. The company estimates net proceeds from the offering will be approximately $242.7 million after underwriting discounts, commissions and estimated offering expenses. The offering is expected to close on or about June 25, 2026, subject to customary closing conditions.

Key Details

• Offering size: 4,945,055 Firm Shares; Optional Shares of 741,758 were fully exercised on June 24, 2026 (total 5,686,813 shares).
• Public offering price: $45.50 per ordinary share.
• Estimated net proceeds: approximately $242.7 million after underwriting discounts, commissions and estimated expenses.
• Underwriter: Leerink Partners LLC (representative); offering made pursuant to prospectus supplement dated June 23, 2026 and company’s Form S-3ASR (filed Jan 7, 2025).

Why It Matters
This transaction provides uniQure with significant additional capital (roughly $243M net) that can be used for clinical development, operations, or other corporate purposes, reducing near-term financing risk. For current shareholders, the offering dilutes existing ownership because new shares are being issued; for potential investors, it signals the company secured institutional underwriting support and rapid exercise of the option. The filing describes standard underwriting terms and customary closing conditions.